Sigma Planning Corp Acquires 4,416 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sigma Planning Corp increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 38,476 shares of the biopharmaceutical company’s stock after buying an additional 4,416 shares during the period. Sigma Planning Corp’s holdings in Gilead Sciences were worth $2,650,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Gilead Sciences by 0.7% during the second quarter. Vanguard Group Inc. now owns 105,017,942 shares of the biopharmaceutical company’s stock worth $7,231,535,000 after buying an additional 754,213 shares in the last quarter. Geode Capital Management LLC lifted its position in Gilead Sciences by 6.0% in the second quarter. Geode Capital Management LLC now owns 21,915,321 shares of the biopharmaceutical company’s stock valued at $1,505,514,000 after purchasing an additional 1,244,015 shares during the last quarter. Parnassus Investments CA raised its stake in shares of Gilead Sciences by 88.5% during the second quarter. Parnassus Investments CA now owns 10,362,033 shares of the biopharmaceutical company’s stock valued at $713,530,000 after acquiring an additional 4,864,272 shares during the last quarter. Legal & General Group Plc lifted its holdings in Gilead Sciences by 10.6% in the 2nd quarter. Legal & General Group Plc now owns 10,297,630 shares of the biopharmaceutical company’s stock worth $709,093,000 after buying an additional 984,246 shares during the period. Finally, Morgan Stanley lifted its stake in Gilead Sciences by 30.4% in the first quarter. Morgan Stanley now owns 9,287,506 shares of the biopharmaceutical company’s stock worth $600,251,000 after acquiring an additional 2,163,164 shares during the period. Hedge funds and other institutional investors own 78.04% of the company’s stock.

In other news, CAO Diane E. Wilfong sold 13,610 shares of the company’s stock in a transaction that occurred on Tuesday, August 17th. The stock was sold at an average price of $72.50, for a total value of $986,725.00. Following the completion of the sale, the chief accounting officer now directly owns 30,179 shares in the company, valued at $2,187,977.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.12% of the stock is owned by corporate insiders.

Several research firms have recently issued reports on GILD. Morgan Stanley lifted their target price on shares of Gilead Sciences from $83.00 to $84.00 and gave the company an “overweight” rating in a report on Tuesday. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $67.00 to $72.00 and gave the company a “market perform” rating in a research note on Friday, July 30th. SVB Leerink raised their price objective on shares of Gilead Sciences from $74.00 to $77.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Oppenheimer began coverage on shares of Gilead Sciences in a report on Monday, June 28th. They issued a “buy” rating and a $100.00 target price for the company. Finally, Royal Bank of Canada restated a “buy” rating and issued a C$84.00 price target on shares of Gilead Sciences in a research note on Monday, August 23rd. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $105.72.

GILD stock opened at $67.63 on Thursday. Gilead Sciences, Inc. has a 12-month low of $56.56 and a 12-month high of $73.34. The business’s 50-day moving average is $70.59 and its 200 day moving average is $68.42. The company has a current ratio of 1.36, a quick ratio of 1.19 and a debt-to-equity ratio of 1.42. The stock has a market cap of $84.80 billion, a price-to-earnings ratio of 16.50, a PEG ratio of 0.63 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, July 29th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Zacks’ consensus estimate of $1.76 by $0.11. The business had revenue of $6.22 billion during the quarter, compared to analysts’ expectations of $6.15 billion. Gilead Sciences had a net margin of 19.38% and a return on equity of 55.94%. During the same period in the prior year, the business earned $1.11 earnings per share. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.15 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 29th. Shareholders of record on Wednesday, September 15th were issued a $0.71 dividend. The ex-dividend date was Tuesday, September 14th. This represents a $2.84 dividend on an annualized basis and a yield of 4.20%. Gilead Sciences’s payout ratio is 40.06%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Read More: What are the risks of holding treasury bonds?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.